VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Other EventsItem 8.01 Other Events.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Other Events
VistaGen Therapeutics, Inc. (the “Company”) today announced that its largest institutional stockholder entered into a 6-month lock-up agreement. Under the agreement, the stockholder and its affiliates agreed not to enter into any transaction involving the Company’s securities during the term of the agreement, which runs through late-October 2017 and covers approximately 36% of the Company’s issued and outstanding equity securities on an as converted basis. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
See Exhibit Index.
About VistaGen Therapeutics, Inc. (NASDAQ:VTGN)
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Recent Trading Information
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) closed its last trading session up +0.24 at 2.22 with 2,964 shares trading hands.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Recent Trading Information
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) closed its last trading session up +0.24 at 2.22 with 2,964 shares trading hands.